Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas: The epic study

Pediatric Pulmonology

Volumn 44, Issue SUPPL. 32, 2009, Pages 183-184

  Hamblett, Nicole M ^a,b   Retsch Bogart, George Z ^c   Treggiari, Miriam ^b   Kronmal, Richard A ^b   Khan, Umer ^a   Williams, Judy ^a   Ramsey, Bonnie W ^a,b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; METHYLXANTHINE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; TOBRAMYCIN;

ARTICLE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; HUMAN; INFECTION CONTROL; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS INFECTION;

EID: 70349761385     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Gibson RL, Burns JL, Ramsey BW. State of the art: pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951. (Pubitemid 37267172)
2. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995;19:10-15.
3. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-161.
4. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001; 32: 277-287. (Pubitemid 32938876)
5. Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol. 2007 Sep;42:751-756
6. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW; for the EPIC Study Group. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009 Jan 14. [Epub ahead of print].